Daniil Shabashvili

TL;DR: Key mechanistic insights are provided into the molecular and biochemical basis of Hip1 function that establish that Hip1 is a serine protease with activity against protein and peptide substrates and position Hip1 as an attractive target for inhibition for developing immunomodulatory therapeutics against Mtb.

TL;DR: Safety of intrapulmonary MYXV delivery with efficient tumor-specific viral replication and cytotoxicity associated with induction of immune cell infiltration is demonstrated and data from 26 SCLC human patients showed negligible immune cell infiltrate, supporting testing MyxV as an ablative and immune-enhancing therapy.

TL;DR: The data show that RER1 influences the trafficking and localization of both γ-secretase and APP, thereby regulating the production and secretion of Aβ peptides, and may be implicated for a safe strategy to target Aβ production.

TL;DR: Recent advances in understanding of the biochemical and structural consequences of DNMT3A mutations on DNA methylation catalysis and binding interactions are discussed and their effects on epigenetic patterns and gene expression changes implicated in the pathogenesis of hematologic malignancies are summarized.

TL;DR: Venugopal et al. as discussed by the authors discussed PARP inhibition as a rational strategy to increase cytarabine efficacy in cells without DNMT3A mutations, while considering the implications of PARP inhibitor resistance for promoting clonal hematopoiesis.